UA78673C2 - Use of lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias - Google Patents

Use of lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias Download PDF

Info

Publication number: UA78673C2
Authority: UA; Ukraine
Prior art keywords: strains; treatment; vaccines; prostatitis; stages
Prior art date: 1999-11-25

Application number

UA2002064624A

Other languages

English (en)

Ukrainian (uk)

Inventor

Karoly Ujchelji

Original Assignee

Vakcina Kft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-25

Filing date

2000-11-23

Publication date

2007-04-25

2000-11-23 Application filed by Vakcina Kft filed Critical Vakcina Kft

2007-04-25 Publication of UA78673C2 publication Critical patent/UA78673C2/uk

Links

206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 14
206010061218 Inflammation Diseases 0.000 title abstract description 3
241000186660 Lactobacillus Species 0.000 title abstract description 3
230000004054 inflammatory process Effects 0.000 title abstract description 3
229940039696 lactobacillus Drugs 0.000 title abstract description 3
210000002307 prostate Anatomy 0.000 title abstract description 3
229960005486 vaccine Drugs 0.000 claims abstract description 26
208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 13
201000007094 prostatitis Diseases 0.000 claims description 13
230000017074 necrotic cell death Effects 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 7
238000000034 method Methods 0.000 claims description 7
239000000725 suspension Substances 0.000 claims description 6
230000000694 effects Effects 0.000 claims description 3
230000001681 protective effect Effects 0.000 claims description 3
238000007918 intramuscular administration Methods 0.000 claims description 2
238000012876 topography Methods 0.000 claims 1
239000000969 carrier Substances 0.000 abstract description 2
239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
238000002360 preparation method Methods 0.000 abstract 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
210000001215 vagina Anatomy 0.000 description 6
241000894006 Bacteria Species 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
239000000203 mixture Substances 0.000 description 5
230000003308 immunostimulating effect Effects 0.000 description 4
239000004310 lactic acid Substances 0.000 description 4
235000014655 lactic acid Nutrition 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
208000005107 Premature Birth Diseases 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
238000002255 vaccination Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
241000705123 Iaria Species 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000006866 deterioration Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
230000001338 necrotic effect Effects 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241001174911 Iasis Species 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
241001150538 Iria Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
206010036590 Premature baby Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
241000224526 Trichomonas Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
208000013507 chronic prostatitis Diseases 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
208000018773 low birth weight Diseases 0.000 description 1
231100000533 low birth weight Toxicity 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
244000005700 microbiome Species 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
239000001393 triammonium citrate Substances 0.000 description 1
235000011046 triammonium citrate Nutrition 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

UA2002064624A 1999-11-25 2000-11-23 Use of lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias UA78673C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU9904408A HU227086B1 (en)	1999-11-25	1999-11-25	Lactobacillus vaccine for treating prostata inflammatory and benign prostata hyperplasia
PCT/HU2000/000122 WO2001037862A2 (en)	1999-11-25	2000-11-23	A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias

Publications (1)

Publication Number	Publication Date
UA78673C2 true UA78673C2 (en)	2007-04-25

Family

ID=90014600

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002064624A UA78673C2 (en)	1999-11-25	2000-11-23	Use of lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias

Country Status (20)

Country	Link
US (4)	US20080175865A1 (cs)
EP (1)	EP1272216B1 (cs)
AT (1)	ATE470452T1 (cs)
AU (1)	AU779214B2 (cs)
CA (1)	CA2394843C (cs)
CZ (1)	CZ302662B6 (cs)
DE (1)	DE60044539D1 (cs)
DK (1)	DK1272216T3 (cs)
EA (1)	EA005198B1 (cs)
ES (1)	ES2348591T3 (cs)
HU (1)	HU227086B1 (cs)
IL (2)	IL149779A0 (cs)
PL (1)	PL201804B1 (cs)
PT (1)	PT1272216E (cs)
RO (1)	RO122760B1 (cs)
RS (1)	RS51201B (cs)
SI (1)	SI20960B (cs)
SK (1)	SK288132B6 (cs)
UA (1)	UA78673C2 (cs)
WO (1)	WO2001037862A2 (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1723965A1 (en) *	2005-05-18	2006-11-22	Stallergenes Sa	Compositions for antigen-specific induction of immuno-tolerance via oral immunization
US9732131B2 (en)	2006-02-27	2017-08-15	Calviri, Inc.	Identification and use of novopeptides for the treatment of cancer
HUP0700552A2 (en)	2007-08-27	2009-03-30	Janos Dr Feher	Method and composition inhibiting inflammation
CN110996970A (zh)	2017-06-02	2020-04-10	亚利桑那州立大学董事会	创建个性化癌症疫苗的方法
US12025615B2 (en)	2017-09-15	2024-07-02	Arizona Board Of Regents On Behalf Of Arizona State University	Methods of classifying response to immunotherapy for cancer
CN111511378A (zh) *	2017-12-19	2020-08-07	杜邦营养生物科学有限公司	用于认知和心理健康的益生菌
EP4038222A4 (en)	2019-10-02	2023-10-18	Arizona Board of Regents on behalf of Arizona State University	Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH639280A5 (de) *	1977-12-23	1983-11-15	Solco Basel Ag	Verfahren zur herstellung einer vakzine gegen das trichomonas-syndrom.
DE19522472C2 (de) *	1995-06-21	1998-07-02	Eugen Baumgaertner	Herstellungsverfahren eines Fermentationsproduktes zur Behandlung von Prostataleiden
ID24734A (id) *	1997-08-21	2000-08-03	New Zealand Dairy Board	Bakteri asam laktat yang meningkatkan kekebalan
IT1298918B1 (it) *	1998-02-20	2000-02-07	Mendes Srl	Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
IT1306716B1 (it) *	1999-06-21	2001-10-02	Mendes S U R L	Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori.

1999
- 1999-11-25 HU HU9904408A patent/HU227086B1/hu unknown
2000
- 2000-11-23 CZ CZ20021771A patent/CZ302662B6/cs not_active IP Right Cessation
- 2000-11-23 SK SK738-2002A patent/SK288132B6/sk not_active IP Right Cessation
- 2000-11-23 EP EP00981507A patent/EP1272216B1/en not_active Expired - Lifetime
- 2000-11-23 EA EA200200602A patent/EA005198B1/ru not_active IP Right Cessation
- 2000-11-23 DE DE60044539T patent/DE60044539D1/de not_active Expired - Lifetime
- 2000-11-23 WO PCT/HU2000/000122 patent/WO2001037862A2/en not_active Ceased
- 2000-11-23 SI SI200020063A patent/SI20960B/sl active Search and Examination
- 2000-11-23 PT PT00981507T patent/PT1272216E/pt unknown
- 2000-11-23 ES ES00981507T patent/ES2348591T3/es not_active Expired - Lifetime
- 2000-11-23 RO ROA200200663A patent/RO122760B1/ro unknown
- 2000-11-23 CA CA2394843A patent/CA2394843C/en not_active Expired - Fee Related
- 2000-11-23 IL IL14977900A patent/IL149779A0/xx unknown
- 2000-11-23 UA UA2002064624A patent/UA78673C2/uk unknown
- 2000-11-23 DK DK00981507.7T patent/DK1272216T3/da active
- 2000-11-23 PL PL355886A patent/PL201804B1/pl unknown
- 2000-11-23 RS YUP-374/02A patent/RS51201B/sr unknown
- 2000-11-23 AU AU18741/01A patent/AU779214B2/en not_active Ceased
- 2000-11-23 AT AT00981507T patent/ATE470452T1/de active
2002
- 2002-05-21 IL IL149779A patent/IL149779A/en not_active IP Right Cessation
2008
- 2008-03-21 US US12/077,780 patent/US20080175865A1/en not_active Abandoned
2011
- 2011-03-16 US US13/049,344 patent/US9056073B2/en not_active Expired - Fee Related
2015
- 2015-06-10 US US14/735,637 patent/US20160051657A1/en not_active Abandoned
2018
- 2018-02-08 US US15/891,620 patent/US20180161414A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUP9904408A2 (hu)	2002-03-28
EA005198B1 (ru)	2004-12-30
WO2001037862A3 (en)	2001-11-22
IL149779A (en)	2009-05-04
US20110243990A1 (en)	2011-10-06
WO2001037862A2 (en)	2001-05-31
HU227086B1 (en)	2010-06-28
YU37402A (sh)	2005-06-10
HUP9904408D0 (en)	2000-01-28
PT1272216E (pt)	2010-09-14
CA2394843A1 (en)	2001-05-31
CZ302662B6 (cs)	2011-08-24
US20180161414A1 (en)	2018-06-14
EA200200602A1 (ru)	2002-10-31
PL201804B1 (pl)	2009-05-29
ES2348591T3 (es)	2010-12-09
AU1874101A (en)	2001-06-04
IL149779A0 (en)	2002-11-10
CA2394843C (en)	2011-01-18
US9056073B2 (en)	2015-06-16
ATE470452T1 (de)	2010-06-15
DE60044539D1 (de)	2010-07-22
EP1272216A2 (en)	2003-01-08
PL355886A1 (en)	2004-05-31
EP1272216B1 (en)	2010-06-09
US20080175865A1 (en)	2008-07-24
SI20960B (sl)	2011-01-31
RS51201B (sr)	2010-12-31
RO122760B1 (ro)	2010-01-29
US20160051657A1 (en)	2016-02-25
SK288132B6 (sk)	2013-10-02
DK1272216T3 (da)	2010-09-27
CZ20021771A3 (cs)	2002-11-13
SI20960A (sl)	2003-02-28
AU779214B2 (en)	2005-01-13
SK7382002A3 (en)	2002-11-06

Publication	Publication Date	Title
Wilson	1967	The hazards of immunization
ES2552153T3 (es)	2015-11-26	Vacuna neumocócica y usos de la misma
TWI272105B (en)	2007-02-01	Cattle reproduction vaccines
JP4718778B2 (ja)	2011-07-06	ウエストナイルワクチン
US20180161414A1 (en)	2018-06-14	Vaccine comprising lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias
CN105535964B (zh)	2019-01-18	一种具有免疫调节作用的双链聚核苷酸—ε-聚赖氨酸—硫酸聚糖复合物及其制备使用方法
SAUER	1933	Immunization with Bacillus pertussis vaccine
CN105664152B (zh)	2019-01-18	一种具有免疫调节作用的双链聚核苷酸—ε-聚赖氨酸复合物及其制备使用方法
JPWO2003009859A1 (ja)	2004-11-11	ヒト免疫療法
JPH04217631A (ja)	1992-08-07	水酸化亜鉛カルシウム、レシチンおよびｐａｏの抗原溶液用アジュバントとしての使用
JP7841077B2 (ja)	2026-04-06	Ｃｌｏｓｔｒｉｄｉｕｍｃｈａｕｖｏｅｉワクチン及び作製方法
Heymann, CS, Kokernot, RH & de Meillon	1958	Wesselsbron virus infections in man
Karsner et al.	1921	Principles of immunology
RU2366455C2 (ru)	2009-09-10	Способ получения специфического иммуномодулятора
Fenton	1927	XXXVI. Recent Vaccine Therapy in Otolaryngology
Abbot	1895	Immunity and Cure
CN111698998A (zh)	2020-09-22	生殖道感染的联合治疗和预防
Rose et al.	1910	A Manual of Surgery for Students and Practitioners
JPH08231422A (ja)	1996-09-10	混合ワクチン
UA125901C2 (uk)	2022-07-06	Ешерихіозно-ентерококова інактивована рідка вакцина проти кишкової палички та ентерокока, спосіб її виготовлення та спосіб лікування і профілактики нею
Cruickshank	1948	Immunisation
MACCARTY	0	The Journal of Laboratory and Clinical Medicine VOL. VIII
BR122015019697B1 (pt)	2018-09-18	composição de vacina para west nile, e uso de plasmídeo com inserções de sequência de dna de vírus west nile na preparação da mesma